Phaseline

Companies › Wuhan Createrna Science and Technology

Wuhan Createrna Science and Technology: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Hematology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MY008211A tablets
Complement pathway inhibitor
–Phase 3Paroxysmal Nocturnal Hemoglobinuria; Paroxysmal Nocturnal Haemoglobinuria (PNH); Paroxysmal Nocturnal Hemoglobinuria (PNH)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06932471MY008211A tabletsPhase 3Paroxysmal Nocturnal HemoglobinuriaHematologyDec 2025
NCT06932744MY008211A tabletsPhase 3Paroxysmal Nocturnal Haemoglobinuria (PNH)HematologyDec 2025
NCT06933914MY008211A tabletsPhase 2Paroxysmal Nocturnal Hemoglobinuria (PNH)HematologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical Gritgen Therapeutics Forma Therapeutics Pharmanutra

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.